Domů › Akutní myeloidní leukemie › Ohio › Columbus
Klinické studie Akutní myeloidní leukemie v Columbus, OH
35 studií pro Akutní myeloidní leukemie hledá účastníky v lokalitách v Columbus a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- a dalších 8
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Probíhá náborFáze 2
- Ohio State University Comprehensive Cancer Center, Columbus
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- Ohio State University Comprehensive Cancer Center, Columbus
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Probíhá náborFáze 3
- Nationwide Children's Hospital, Columbus
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Probíhá náborFáze 1/2
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Probíhá náborFáze 1
- Ohio State University, The James Comprehensive Cancer, Columbus
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Probíhá náborFáze 1/2
- The Ohio Sate University, Columbus
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Probíhá náborFáze 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Probíhá náborObservační studie
- OhioHealth Research Institute, Columbus
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Probíhá náborFáze 3
- US-Colombus OH-OSU, Columbus
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Probíhá náborFáze 3
- US-Colombus OH-OSU, Columbus
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Probíhá náborFáze 2
- Ohio State University Comprehensive Cancer Center, Columbus
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Probíhá náborFáze 1
- Ohio State University, Columbus
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Probíhá náborFáze 1
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Probíhá náborFáze 1/2
- Nationwide Children's Hospital, Columbus
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Probíhá náborFáze 3
- Nationwide Children's Hospital, Columbus
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Probíhá náborFáze 3
- Ohio State University, Columbus
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Probíhá náborObservační studie
- Nationwide Children's Hospital, Columbus
- The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Probíhá náborFáze 2
- Ohio State University Comprehensive Cancer Center, Columbus
Ivosidenib as Post-HSCT Maintenance for AML
Probíhá náborFáze 2
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Probíhá náborFáze 1
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Probíhá náborFáze 1
- The Ohio State University, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Probíhá náborFáze 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Probíhá náborFáze 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Probíhá náborFáze 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Ziftomenib Maintenance Post Allo-HCT
Probíhá náborFáze 1
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Probíhá náborFáze 1
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Probíhá náborFáze 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
Probíhá náborObservační studie
- The Ohio State University Medical Center, Columbus
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1/2
- The Ohio State University Wexner Medical Center, Columbus
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Probíhá náborVítáni zdraví dobrovolníci
- Ohio State University, Columbus
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Probíhá náborFáze 1/2
- Nationwide Children's Hospital, Columbus
Studie Akutní myeloidní leukemie v jiných městech
- Houston, TX85 studií
- New York City, NY51 studií
- Boston, MA44 studií
- Baldwin Park, CA40 studií
- Seattle, WA40 studií
- Philadelphia, PA34 studií
- Durham, NC33 studií
- Atlanta, GA30 studií
- Tampa, FL29 studií
- Chicago, IL26 studií
- Portland, OR25 studií
- Miami, FL24 studií
Další studie v Columbus
- Nemalobuněčný plicní karcinom56 studií
- Rakovina prsu39 studií
- Rakovina vaječníků39 studií
- Rakovina (všechny typy)38 studií
- Rakovina plic37 studií
- Chronická lymfocytární leukemie28 studií
- Metastatický karcinom27 studií
- Rakovina endometria25 studií
- Kolorektální karcinom24 studií
- Rakovina prostaty24 studií
- Mnohočetný myelom24 studií
- Melanom21 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.